DE66144T1 - Benzylazole-derivate. - Google Patents

Benzylazole-derivate.

Info

Publication number
DE66144T1
DE66144T1 DE198282104196T DE82104196T DE66144T1 DE 66144 T1 DE66144 T1 DE 66144T1 DE 198282104196 T DE198282104196 T DE 198282104196T DE 82104196 T DE82104196 T DE 82104196T DE 66144 T1 DE66144 T1 DE 66144T1
Authority
DE
Germany
Prior art keywords
compound
alkyl
independently
atoms
hydrogen atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE198282104196T
Other languages
English (en)
Inventor
Masaru Kobe-Shi Hyogo Pref. Ogata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of DE66144T1 publication Critical patent/DE66144T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (7)

VOSSIUSVOSSIUSTA UC HNER · HEUNEMANN · RAUH PATENTANWÄLTE SIEBERTSTRASSE A-800 0 MÜNCHEN BS · PHONE: (O89) *7 4O75 CABLE: BEN ZOLPATENT MDNCHEN · TELEX S- 29 453 VOPAT D u.Z.: R 829 EP EP 82 10 4196.9 Shionogi & Co., Ltd. 0 066 1AA Deutsche übersetzung der Patentansprüche gemäß Art. 67 (1) EPÜ Patentansprüche
1. Eine Verbindung der allgemeinen Formel I
Y-if?7f ^ ^ V= Ο)
(wobei
A einen 5- oder 6-gliedrigen ungesättigten heterocyclischen Rest mit 1 bis 3 Stickstoffatomen oder eine Benzimidazolylgruppe bedeutet, gegebenenfalls jeweils substituiert durch 1 bis 3 Oxogruppen, Cj-C.-Alkyl-, C1-C4-AIkOXy- oder C--C,--Alkoxycarbonylreste oder Halogenatome; B \ 3 oder >. ^ „ darstellt
•" , I ^C=CR R
3 4 5
in denen R , R und R unabhängig voneinander Wasserstoffatome oder C1-C.-Alkylreste sind;
1 1 *
R einen C1-C.-Alkylrest bedeutet;
R ein Wasserstoffatom oder einen C1-C4~Alkylrest darstellt; oder
1 2
R -N-R eine Pyrrolidinyl-, Piperidino-, Piperazino- oder
L J
0066Η4
Morpholinogruppe ist; und
X/ Y und Z unabhängig voneinander Wasserstoff atome/ C..-C.-Alkyl- oder Cj-C^-Alkoxyreste oder Halogenatome darstellen)
und pharmazeutisch verträgliche Säureadditionssalze davon.
2. Eine Verbindung der allgemeinen Formel Ia
OH
Yü Ii (la)
(in der
E und E1 unabhängig voneinander Wasserstoffatome, C1-C3-Alkyl- oder C~-C,-Älkoxycarbonylreste sind, R einen C3-C.-Alkylrest bedeutet; und X und Y unabhängig voneinander Wasserstoffatome, Methyl- oder Methoxygruppen oder Chloratome sind).
3. Eine Verbindung nach Anspruch 1, nämlich 1- \2,5-Dichlor-6-/Ί-(1-imidazolyl)-vinyl7-phenoxy]-S-isopropylamino^- propanol»
25
4. Eine Verbindung nach Anspruch 1, nämlich 1-^2 ,5-Dichlor- 6-£"\~ (1-imidazolyl) -vinyl^-phenoxyl -3-isopropylamino-2-propanol.
5. Verfahren zur Herstellung der Verbindungen gemäß Anspruch 1, das umfaßt Umsetzung einer Verbindung der Formel
.O1
L J
γ 0066ΗΑ "i
(in der A, B, X, Y und Z die gleiche Bedeutung wie vorstehend angegeben haben) mit einer Verbindung der Formel
1
_ R-NH-R
(in der R und R die gleiche Bedeutung wie vorstehend angegeben haben)
in Gegenwart oder Abwesenheit eines Lösungsmittels bei einer Temperatur von etwa 25°C bis etwa 1000C. 10
6. Arzneimittel, enthaltend eine wirksame Menge einer Verbindung gemäß Anspruch 1 bis 4 und pharmazeutisch verträgliche Verdünnungsmittel, Träger und/oder Hilfsstoffe.
7. Verwendung einer Verbindung gemäß Anspruch 1 bis zur Herstellung eines Arzneimittels für die Behandlung von Arrhythmie, zur Prophylaxe von Angina pectöris und zur Behandlung von Thrombosen.
L J
DE198282104196T 1981-05-14 1982-05-13 Benzylazole-derivate. Pending DE66144T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56072986A JPS57188570A (en) 1981-05-14 1981-05-14 Benzylazole derivative

Publications (1)

Publication Number Publication Date
DE66144T1 true DE66144T1 (de) 1983-05-26

Family

ID=13505217

Family Applications (2)

Application Number Title Priority Date Filing Date
DE198282104196T Pending DE66144T1 (de) 1981-05-14 1982-05-13 Benzylazole-derivate.
DE8282104196T Expired DE3269141D1 (de) 1981-05-14 1982-05-13 Benzylazole derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8282104196T Expired DE3269141D1 (de) 1981-05-14 1982-05-13 Benzylazole derivatives

Country Status (16)

Country Link
US (1) US4430331A (de)
EP (1) EP0066144B1 (de)
JP (1) JPS57188570A (de)
KR (1) KR860001580B1 (de)
AU (1) AU554243B2 (de)
CA (1) CA1193255A (de)
DE (2) DE66144T1 (de)
DK (1) DK161317C (de)
ES (1) ES8303400A1 (de)
GB (1) GB2103600B (de)
HU (1) HU188059B (de)
IE (1) IE52989B1 (de)
IL (1) IL65735A (de)
NZ (1) NZ200471A (de)
PH (1) PH17989A (de)
ZA (1) ZA823207B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3343671A1 (de) * 1983-12-02 1985-06-20 Basf Ag, 6700 Ludwigshafen Aminopropanolderivate von substituierten 2-hydroxy-propiophenonen, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870726A (en) 1970-09-09 1975-03-11 Bayer Ag Derivatives of 3-azolylpropyne and processes for their preparation and use
CH584695A5 (en) * 1973-02-20 1977-02-15 Ciba Geigy Ag 3-amino-2-hydroxypropoxy substd. diazines and pyridines - with beta-adrenergic blocking or stimulating activity
SE7601713L (sv) * 1975-03-03 1976-09-06 Merck & Co Inc Nya, substituerad imidazoler
DK464278A (da) * 1977-10-19 1979-04-20 Wellcome Found Imidazolderivater og salte deraf samt fremgangsmaade og mellemprodukter til deres fremstilling
US4210653A (en) * 1978-06-27 1980-07-01 Merck & Co., Inc. Pyridyloxypropanolamines
JPS5951943B2 (ja) * 1978-08-21 1984-12-17 キツセイ薬品工業株式会社 新規なイミダゾ−ル誘導体
GB2041363B (en) * 1979-01-19 1982-10-06 Pfizer Ltd N-benzyl-imidazoles
DK157860C (da) * 1979-06-07 1990-07-30 Shionogi & Co Analogifremgangsmaade til fremstilling af benzylimidazolderivater samt farmaceutisk acceptable syreadditionssalte deraf
EP0034116A3 (de) * 1980-02-11 1981-09-02 Berlex Laboratories, Inc. N-(3-Phenoxy-2-hydroxypropyl)benzimidazol-1-alkanamine
CA1156661A (en) * 1980-02-25 1983-11-08 Hoffmann-La Roche Limited Phenoxy-aminopropanol derivatives

Also Published As

Publication number Publication date
GB2103600B (en) 1985-01-09
IL65735A (en) 1986-04-29
EP0066144A2 (de) 1982-12-08
CA1193255A (en) 1985-09-10
GB2103600A (en) 1983-02-23
IE52989B1 (en) 1988-04-27
DK161317B (da) 1991-06-24
PH17989A (en) 1985-02-28
EP0066144A3 (en) 1983-11-30
DK216282A (da) 1982-11-15
DK161317C (da) 1991-12-30
IL65735A0 (en) 1982-08-31
JPS6325583B2 (de) 1988-05-26
ES512151A0 (es) 1983-02-01
DE3269141D1 (de) 1986-03-27
AU554243B2 (en) 1986-08-14
AU8318082A (en) 1982-11-18
EP0066144B1 (de) 1986-02-19
US4430331A (en) 1984-02-07
ZA823207B (en) 1983-03-30
IE821134L (en) 1982-11-14
HU188059B (en) 1986-03-28
JPS57188570A (en) 1982-11-19
ES8303400A1 (es) 1983-02-01
KR830010079A (ko) 1983-12-26
NZ200471A (en) 1985-08-30
KR860001580B1 (ko) 1986-10-10

Similar Documents

Publication Publication Date Title
DE1056725T1 (de) Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
DE2318021A1 (de) Neue krebsmittel
DE2744423B2 (de) Verfahren zur Herstellung von Benzothiazolylsulfenamiden
DE1620449C3 (de) Substituierte Benzimidazole und Verfahren zu ihrer Herstellung
DE66144T1 (de) Benzylazole-derivate.
DE2921660A1 (de) 5-nitroimidazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende antiprotozoen-mittel
DE1695271A1 (de) Schaedlingsbekaempfungsmittel
DE2342881A1 (de) 5-methylthiopyrimidine, verfahren zu ihrer herstellung und ihre verwendung
DE1470009A1 (de) 3,5-Dihydro-5-phenyl-4,1-benzoazepin-2-one
DE3008318A1 (de) Theobromin-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittelzusammensetzungen
DE73155T1 (de) Antitumorwirkende verbindungen.
DE3148122A1 (de) "1-benzylimidazolderivate, verfahren zu ihrer herstellung, arzneimittel und fungizide mittel"
DE1770156B2 (de) N-pyridyl-forminimoaether, verfahren zu ihrer herstellung und ihre verwendung
DE2012219A1 (de) Substituierte Benzimidazole
DE2065043C3 (de) N-(33-Dichlorphenyl)- und N-O5-Dibromphenyl)-4-iminooxazolidin-2-on-Verbindungen und ihre Verwendung als Fungicide
DE3413660A1 (de) Verfahren zur herstellung von 2-(trialkyl-silyl)-ergolinderivaten
DE3135831A1 (de) 9,10-substituierte 2-mesitylimino-3-alkyl-3,4,6,7-tetrahydro-2h-pyrimido(6,1-a)isochinolin-4-one, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE124777T1 (de) Derivate des 1,4-dihydropyridins.
EP0353416A2 (de) Verwendung von Ajoen und Ajoen-Derivaten als Cytostatika
DE35259T1 (de) Tetrahydrothiopyrano(3,2-b)indolderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzung
AT350564B (de) Verfahren zur herstellung von neuen 2-(4h-1,2,4 -triazolyl)-benzophenonen und deren salzen
DE2747303A1 (de) Beta-lactame, verfahren zu ihrer herstellung, zwischenprodukte bei diesen verfahren, und derivate dieser verbindungen
AT278837B (de) Verfahren zur Herstellung von neuen 4-[5-Nitrothiazolyl-(2)]-thiomorpholin-1-oxyden und 1,1-dioxyden
DE4831T1 (de) 2,6-Dialkoxybenzamide, Zwischenprodukte, Verfahren zu ihrer Herstellung, Zusammensetzungen und Behandlungsverfahren von Psychosen
DE948330C (de) Verfahren zur Herstellung von Derivaten des AEthylenimins